Platelet glycoprotein IIb/IIIa antagonists in clinical trials for the treatment of coronary artery disease.
There is a growing understanding of the central role that platelets play in coronary artery disease. The glycoprotein IIb/IIIa receptor has recently been identified as the final common pathway for platelet aggregation and hence has been the focus of many clinical trials to influence various aspects of coronary artery disease. In this report we give an overview of these clinical trials.
Salam
Amar M
AM
Department of Cardiology and Cardiovascular Surgery, Hamad Medical Corporation, Doha, Qatar.
Suwaidi
Jassim Al
JA
D000284:Administration, Oral; D000818:Animals; D002986:Clinical Trials as Topic / Q000379:methods / Q000706:statistics & numerical data; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007275:Injections, Intravenous; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors* / Q000378:metabolism; D016032:Randomized Controlled Trials as Topic / Q000379:methods / Q000706:statistics & numerical data
D019039:Platelet Glycoprotein GPIIb-IIIa Complex